Published in Nat Med on October 31, 2004
The science of stroke: mechanisms in search of treatments. Neuron (2010) 6.14
Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis (2010) 1.90
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A (2005) 1.59
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem (2010) 1.48
Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A (2005) 1.45
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A (2008) 1.45
Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin. Arterioscler Thromb Vasc Biol (2014) 1.41
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood (2010) 1.30
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost (2005) 1.23
Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res (2006) 1.22
Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function. J Neurochem (2008) 1.21
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke (2008) 1.15
Protein C anticoagulant and cytoprotective pathways. Int J Hematol (2012) 1.14
Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cereb Blood Flow Metab (2008) 1.10
Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol (2009) 1.07
Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med (2011) 1.03
Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J (2005) 1.02
Deleterious effects of plasminogen activators in neonatal cerebral hypoxia-ischemia. Am J Pathol (2008) 1.01
An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci (2013) 1.00
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One (2010) 1.00
Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res (2010) 1.00
Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem (2009) 0.99
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab (2011) 0.99
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity. J Cereb Blood Flow Metab (2010) 0.99
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des (2012) 0.98
Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact. Neurosurgery (2010) 0.98
Activated protein C action in inflammation. Br J Haematol (2009) 0.98
The protein C pathway and pathologic processes. J Thromb Haemost (2009) 0.97
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke (2011) 0.94
PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats. Neurobiol Dis (2012) 0.93
Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci (2010) 0.93
ADAMTS13 gene deletion enhances plasma high-mobility group box1 elevation and neuroinflammation in brain ischemia-reperfusion injury. Neurol Sci (2012) 0.92
Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke (2013) 0.91
Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Res (2013) 0.89
Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion. Am J Transl Res (2009) 0.88
Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener (2011) 0.88
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain (2009) 0.87
Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis. Stroke (2009) 0.85
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol (2017) 0.84
Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb Haemost (2014) 0.84
Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells. Cell Mol Neurobiol (2008) 0.84
Oxidative Stress and the Use of Antioxidants in Stroke. Antioxidants (Basel) (2014) 0.84
Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des (2012) 0.83
Activated protein C: A regulator of human skin epidermal keratinocyte function. World J Biol Chem (2014) 0.82
Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model. Graefes Arch Clin Exp Ophthalmol (2007) 0.82
Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells Mol Dis (2013) 0.81
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity. J Thromb Haemost (2013) 0.81
Impacts of tissue-type plasminogen activator (tPA) on neuronal survival. Front Cell Neurosci (2015) 0.80
Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. Front Cell Neurosci (2015) 0.80
Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers. Mol Neurobiol (2014) 0.79
Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. Thromb Res (2016) 0.78
Combination stroke therapy: easy as APC? Nat Med (2004) 0.78
Diverse impact of acute and long-term extracellular proteolytic activity on plasticity of neuronal excitability. Front Cell Neurosci (2015) 0.77
Does treatment with t-PA increase the risk of developing epilepsy after stroke? J Neurol (2015) 0.77
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke. PLoS One (2015) 0.76
Safety threshold of intravitreal activated protein-C. Graefes Arch Clin Exp Ophthalmol (2010) 0.76
Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13. Sci Rep (2016) 0.75
Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke. J Atheroscler Thromb (2016) 0.75
2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. Arterioscler Thromb Vasc Biol (2016) 0.75
Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury. PLoS One (2017) 0.75
Tissue plasminogen activator mediates deleterious complement cascade activation in stroke. PLoS One (2017) 0.75
Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell (2008) 7.79
The cytoprotective protein C pathway. Blood (2006) 5.75
Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron (2010) 5.20
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci (2008) 3.78
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol (2009) 2.85
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med (2005) 2.71
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem (2004) 2.45
Studies on expression and function of the TMEM16A calcium-activated chloride channel. Proc Natl Acad Sci U S A (2009) 2.33
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
TMEM16F forms a Ca2+-activated cation channel required for lipid scrambling in platelets during blood coagulation. Cell (2012) 2.24
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2007) 2.17
Characterization of hemoglobin, water, and NIR scattering in breast tissue: analysis of intersubject variability and menstrual cycle changes. J Biomed Opt (2004) 2.17
APC and GSK-3beta are involved in mPar3 targeting to the nascent axon and establishment of neuronal polarity. Curr Biol (2004) 2.09
Effects of dietary sodium and genetic background on angiotensinogen and Renin in mouse. Hypertension (2002) 2.00
Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A (2007) 1.91
Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J (2003) 1.91
RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke (2004) 1.89
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol (2008) 1.83
Image analysis methods for diffuse optical tomography. J Biomed Opt (2006) 1.82
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab (2007) 1.64
Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol (2008) 1.62
Statistical analysis of nonlinearly reconstructed near-infrared tomographic images: Part I--Theory and simulations. IEEE Trans Med Imaging (2002) 1.59
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Ion exchangers NHX1 and NHX2 mediate active potassium uptake into vacuoles to regulate cell turgor and stomatal function in Arabidopsis. Plant Cell (2012) 1.54
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener (2010) 1.49
Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost (2008) 1.49
Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol (2012) 1.45
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A (2008) 1.45
Effect of hyperhomocysteinemia on protein C activation and activity. Blood (2002) 1.45
A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J Neurosci Methods (2003) 1.44
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol (2002) 1.38
Impact of Hospital Admission Care At a Pediatric Unit: A Qualitative Study. Pediatr Nurs (2016) 1.38
Neurodegeneration and the neurovascular unit. Nat Med (2010) 1.37
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A (2012) 1.34
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.32
High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation (2005) 1.31
Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood (2010) 1.30
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem (2002) 1.30
Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One (2010) 1.28
Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol (2005) 1.26
Renin and kallikrein in connecting tubule of mouse. Kidney Int (2003) 1.22
The AtNHX1 exchanger mediates potassium compartmentation in vacuoles of transgenic tomato. Plant J (2009) 1.21
Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.19
Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods (2004) 1.19
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog (2010) 1.16
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke (2008) 1.15
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis (2003) 1.15